ONO 4053

Drug Profile

ONO 4053

Alternative Names: ONO-4053

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiallergics
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 04 Mar 2016 Efficacy data from a phase II trial in Allergic rhinitis presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 13 May 2015 Phase-II development is ongoing in Japan and overseas for Allergic rhinitis
  • 13 May 2015 Phase-II clinical trials in Allergic rhinitis in Japan prior to May 2015 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top